Comparison · NCT03203642-604acf7a
Tesevatinib vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tesevatinib vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs). Trial comparisons, record NCT03203642-604acf7a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03203642-604acf7a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.974 | 0.865 | 0.995 | wilson | |
| Risk in group 2 | 1 | 0.912 | 1 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0263 | -0.135 | 0.0639 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.974 | 0.924 | 1.03 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on Tesevatinib than on Placebo | 38 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tesevatinib | Participants received tesevatinib 50 mg tablet orally QD for up to 25.3 months. | 37 | 38 | OG000 |
| Group 2 | Placebo | Participants received placebo matched to tesevatinib tablet orally QD for up to 25.3 months. | 40 | 40 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)
- Description
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal product and which did not necessarily had to have a causal relationship with the treatment. TEAEs were AEs that developed or worsened or became serious from the first dose (Day 1) of the study drug until end of study.
- Time frame
- From Baseline (Day 1) up to 30 days post last dose of study drug (i.e., up to 26 months)
- Population
- Analysis was performed on safety population which included all participants who received at least 1 dose of study drug and were analyzed according to the study drug they actually received.
Source ClinicalTrials.gov
Trial
- Title
- Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
- NCT number
- NCT03203642
- Phases
- PHASE2
- Conditions
- Autosomal Dominant Polycystic Kidney, ADPKD
- Interventions
- Tesevatinib, Placebo
- Lead sponsor
- Kadmon, a Sanofi Company
- Results first posted
- 2023-02-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03203642?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03203642-604acf7a